Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Beijing Anshi Biotechnology Co

Request full access

Anshi Biotechnology is committed to the health service industry and aims to provide patients with high-quality pharmaceutical products

ChinaBiotech & Life Sciences

About Beijing Anshi Biotechnology Co

Avistone Biotechnology is a pioneering biopharmaceutical company focused on developing innovative treatments for advanced non-small cell lung cancer (NSCLC) with cMET alterations. Operating in the highly specialized oncology market, Avistone serves patients and healthcare providers by advancing precision medicine through targeted therapies. The company’s business model revolves around the research, development, and commercialization of novel drugs, with revenue generated from clinical trials, licensing agreements, and eventual drug sales. Avistone's flagship products include cMET inhibitors like bozitinib and vebreltinib, which are currently undergoing rigorous clinical trials to ensure efficacy and safety. By leveraging cutting-edge science and strategic partnerships, Avistone aims to address unmet medical needs and improve patient outcomes in the oncology space.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Dec 2023 $138M $550M Cathay Capital · Bain Capital · Yanchuang Capital · IDG Capital ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Beijing Anshi Biotechnology Co website traffic

Latest recorded traffic for Beijing Anshi Biotechnology Co is 920 monthly website visits, up 240.7% over the last three months.

Latest monthly visits920 3-month web change+240.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Beijing Anshi Biotechnology Co in its local ecosystem

Live from Dealroom

The Beijing Anshi Biotechnology Co office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Beijing Anshi Biotechnology Co on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Beijing Anshi Biotechnology Co’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.